Kahan B D, Pellis N R, LeGrue S J, Tanaka T
Cancer. 1982 Mar 15;49(6):1168-73. doi: 10.1002/1097-0142(19820315)49:6<1168::aid-cncr2820490617>3.0.co;2-o.
Active immunotherapy with materials extracted from a murine methylcholanthrene-induced sarcoma using single phase solutions of 2.5% 1-butanol evoked host resistance against supralethal burdens of neoplastic cells deposited subcutaneously or delivered hematogenously. After curative resection of progressing 1 cm tumors, postsurgical immunity against subsequent subcutaneous neoplastic challenges was potentiated by weekly injections of crude butanol extracts. In a conventional therapy model, hosts bearing progressing 4 mm subcutaneous tumors displayed neoplastic regression following chemoimmunotherapy with cyclosphosphamide and tumor extracts. Therapeutic effects were demonstrated not only against subcutaneous neoplasms, but also against hematogenously disseminated pulmonary and extrapulmonary metastases introduced by intravenous inoculation of sarcoma cells. These findings suggest that tumor extracts may afford potent therapeutic adjuvants for patients bearing a small body tumor burden but at high risk of disease recurrence.
用从鼠甲基胆蒽诱导的肉瘤中提取的物质进行主动免疫治疗，使用2.5%正丁醇的单相溶液可诱发宿主对皮下接种或血源性输送的超致死量肿瘤细胞负担产生抵抗力。在对进展期1厘米肿瘤进行根治性切除后，每周注射粗制丁醇提取物可增强术后对随后皮下肿瘤挑战的免疫力。在传统治疗模型中，患有进展期4毫米皮下肿瘤的宿主在接受环磷酰胺和肿瘤提取物的化学免疫治疗后出现肿瘤消退。治疗效果不仅体现在皮下肿瘤上，还体现在通过静脉接种肉瘤细胞引入的血源性播散性肺和肺外转移瘤上。这些发现表明，肿瘤提取物可能为身体肿瘤负担小但疾病复发风险高的患者提供有效的治疗佐剂。
